Wei Wang

Institute of Life Science,Jiyang College of Zhejiang A&F University, zhuji, 311800, China
Author    Correspondence author
Bioscience Methods, 2024, Vol. 15, No. 1   doi: 10.5376/bm.2024.15.0005
Received: 11 Jan., 2024    Accepted: 16 Feb., 2024    Published: 28 Feb., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Wang W., 2024, AI based drug screening process: from data mining to candidate drug validation, Bioscience Method, 14(1): 37-49 (doi: 10.5376/bm.2024.15.0005)

With the rapid development of artificial intelligence (AI) technology, its application in drug research and development is becoming increasingly widespread. This study introduces the advantages of AI technology in drug screening, such as fast processing and analysis of large amounts of data, improving screening accuracy, and reducing research and development costs. Discussed the shortcomings in the current AI drug screening process, such as data dependence, insufficient model interpretability, and legal and ethical issues. Intended to explore the AI based drug screening process, from data mining to candidate drug validation. I hope to provide a comprehensive and systematic perspective for researchers and practitioners in the field of drug development by deeply understanding the advantages, disadvantages, and challenges faced by AI technology in drug screening, and proposing corresponding solutions, in order to guide them to better utilize AI technology to accelerate the drug development process.

Artificial intelligence; Drug screening; Data mining; Candidate drug validation; Drug development